WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Goldman flagged Morgan Stanley over HK block trades https://www.thestandard.com.hk/section-news/section/2/241014/Goldman-flagged-Morgan-Stanley-over-HK-block-trades Goldman Sachs reported Morgan Stanley to Hong Kong's financial regulator over a series of block trades by its rival three years ago, the Financial Times reported, citing people familiar with the matter. ... Trades including Wuxi Biologics Cayman (2269) stock are among those flagged and it's not clear whether the authorities investigated the claim by individuals at Goldman, according to the paper. ... Morgan Stanley executed nine block trade transactions for Wuxi between 2020 and 2021, the FT reported, citing Bloomberg data. There is no suggestion of wrongdoing by Wuxi. The Chinese company did not respond to the newspaper's request for comment.

http://www.aastocks.com/en/stocks/news/aafn-con/RUM.220421_135430/company-news

Changes in Hong Kong Stocks | WuXi Biologics (02269) Down 10% Overseas New Crown Vaccine Manufacturers Adjust Sales Expectations https://m.jrj.com.cn/madapter/hk/2022/04/21141336418607.shtml

https://hk.investing.com/news/stock-market-news/article-226181

WuXi Biologics (02269) Subsidiary Granted 53,067,270 Share Options https://m.jrj.com.cn/madapter/hk/2022/04/03180836251930.shtml

BlackRock reduzierte seine Bestände von etwa 979.200 Aktien von WuXi Biologics (02269 HK) zu etwa 55,14 HK$ pro Aktie -> 22.03. https://m.sohu.com/a/533365103_121319643/?pvid=000115_3w_a Morgan Stanley: Raised the target price of WuXi Biologics (2269 HK) to HK$86 with an overweight rating https://m.jrj.com.cn/madapter/hk/2022/03/28131235846160.shtml

WuXi Bio grabs larger piece of the bio CDMO pie https://bioprocessintl.com/bioprocess-insider/global-markets/wuxi-bio-grabs-larger-piece-of-the-bio-cdmo-pie/ Credit Suisse: Maintain "Outperform" rating on WuXi Biologics (02269), target price down to HK$110 https://m.jrj.com.cn/madapter/hk/2022/03/25121135078884.shtml

https://wap.eastmoney.com/a/202203232320263176.html

https://hk.investing.com/news/stock-market-news/article-222049

WuXi Biologics Achieved Record Growth and Profitability in 2021 https://www.prnewswire.com/news-releases/wuxi-biologics-achieved-record-growth-and-profitability-in-2021-301508083.html Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to US$13,597 Million ....

https://m.jrj.com.cn/madapter/hk/2022/03/22201234862242.shtml

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021 https://doc.irasia.com/listco/hk/wuxibiologics/annual/2021/res.pdf

http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1169873/1

Yamato: Upgrading WuXi Biologics (02269) to “Buy” and lowering the target price to HK$72 https://finance.sina.cn/hkstock/ggpj/2022-03-18/detail-imcwipih9178908.d.html?from=wap

https://finance.sina.cn/hkstock/ggpj/2022-03-17/detail-imcwipih9058299.d.html?from=wap ... Considering that CXO companies are not affected by the temporary slowdown in medical terminal demand, and WuXi PharmaTech (2359 HK), Tigermed (3347 HK), and Asymchem (6821 HK) have recently announced that they will be in January-February 2022 New orders increased significantly year-on-year, indicating that the industry's prosperity is still high. We still recommend WuXi AppTec (2359 HK) and WuXi Biologics (2269 HK).  ... The share price of WuXi Biologics (2269 HK) has already reflected the impact of two of its subsidiaries being included in the "unverified list" by the United States earlier. ... Therefore, the actual impact of the US policy on the company's operation is controllable at present. We maintain a "buy" rating and a target price of HK$114.66.